Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation 2

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2385Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1833Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1017Vincristine 964Cetuximab 945Trastuzumab 945Prednisone 942Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
2'-((4'-trifluoromethanesulfonyloxy)phenyl)-N-methanesulfonylpropionamide × Clear all
NCT05815173 2025-12-30

Ladarixin With Sotorasib in Advanced NSCLC

NYU Langone Health

Phase 1 Recruiting
40 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

NCT05815186 2024-03-29

Ladarixin With Sotorasib in Advanced NSCLC - Phase II

NYU Langone Health

Phase 2 Withdrawn
Thoracic

Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡